Investors
We welcome investors and partners who share our passion for rapid and economically viable DRPx-innovation and clinical development. If you share this passion and have interest to join us on the journey, please contact us.
With FexoTopic (OP2101) we are now moving on to a phase 2A proof-of-concept study. The Atopic Dermatitis market is currently highly genericized, and no distinct trends in corporate strategy exist. However, over the coming decade the introduction of new drugs will emerge as a key future strategy for this marketplace. Unmet needs include the lack of therapeutic options, better long-term disease control and management, more tolerable topical treatment options, and improved patient treatment compliance. Our market analysis shows a significant opportunity to capture a share of this $5 billion-dollar annual market with a lotion that is safe, effective and economically attractive to payors.
Our target portfolio is focused on exploring the untapped potential of Fexofenadine. It comprises six drug concepts potentially covering up to 12 indications. We welcome partners and investors who share our excitement to bring these concepts to clinical development. Fexofenadine is just the start of our passion for DRPx innovation.
With FexoTopic (OP2101) we are now moving on to a phase 2A proof-of-concept study. The Atopic Dermatitis market is currently highly genericized, and no distinct trends in corporate strategy exist. However, over the coming decade the introduction of new drugs will emerge as a key future strategy for this marketplace. Unmet needs include the lack of therapeutic options, better long-term disease control and management, more tolerable topical treatment options, and improved patient treatment compliance. Our market analysis shows a significant opportunity to capture a share of this $5 billion-dollar annual market with a lotion that is safe, effective and economically attractive to payors.
Our target portfolio is focused on exploring the untapped potential of Fexofenadine. It comprises six drug concepts potentially covering up to 12 indications. We welcome partners and investors who share our excitement to bring these concepts to clinical development. Fexofenadine is just the start of our passion for DRPx innovation.
